# A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

> **NCT06588855** · PHASE3 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 350 (estimated)

## Conditions studied

- Moderately to Severely Active Ulcerative Colitis

## Interventions

- **DRUG:** Afimkibart
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06588855
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-11
- **Primary completion:** 2027-01-30
- **Final completion:** 2031-01-30
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06588855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06588855, "A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06588855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*